Analyst Price Target is $100.31
▲ +142.89% Upside Potential
This price target is based on 18 analysts offering 12 month price targets for Arvinas in the last 3 months. The average price target is $100.31, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 142.89% upside from the last price of $41.30.
Current Consensus is
Buy
The current consensus among 18 polled investment analysts is to buy stock in Arvinas. This Buy consensus rating has held steady for over two years.
Arvinas, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead product candidates include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC); ARV-471, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer; and ARV-766 an investigational orally bioavailable PROTAC protein degrader for the treatment of men with mCRPC. The company has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Arvinas, Inc. was founded in 2013 and is based in New Haven, Connecticut.
Read More